GYRE
GYRE THERAPEUTICS, INC.
Next earnings Aug 10, 2026 · consensus $-0.09 EPS, $27.0M rev
Last earnings -12.1% on 2026-05-07
$6.29
▲ +0.96%$6.29▼ -19.05%
over 1Y
L $5.56EODHDH $8.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.0%
1W+2.6%
1M+6.3%
3M-7.2%
YTD-7.6%
1Y-19.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 10.2% YoY.
Revenue (FY2025) $117M · FY2025
The read
Middling fundamentals and a rich price (~97% above fair value) leave little margin of safety — a wait-and-see.
GYRE THERAPEUTICS, INC. shows $117M in FY2025 revenue (+10.2% YoY), a 8.5% net margin, and 9.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $7.34M | $102M | $113M | $106M | $117M |
| Gross profit | — | $97.5M | $109M | $102M | — |
| Operating income | -$87.9M | $9.20M | -$67.2M | $16.2M | $11.5M |
| Net income | -$87.9M | $4.31M | -$85.5M | $17.9M | $9.88M |
| Diluted EPS | -$2.87 | $0.03 | -$1.41 | $0.05 | $0.02 |
| Net margin | -1198.3% | 4.2% | -75.3% | 16.9% | 8.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$574M
EV / EBITDA41.1
EV / Sales4.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield1.6%
FCF yield-0.0%
Quality & risk
ROIC (est.)8.5%
Free cash flow-$180K
Total debt$853K
Net cash$36.2M
Altman Z-Score16.30 safe
Piotroski F-Score4/9
Capital returns
Buyback yield0.0%
Dividend yield (est.)7.4%
Shareholder yield7.4%
Shares Δ YoY+3.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- S-3 Shelf registration (potential raise)2026-06-23
- 8-K Shareholder vote2026-06-16
- 8-K Reg FD disclosure2026-06-02
- 8-K Reg FD disclosure2026-05-14
- 8-K Reg FD disclosure2026-05-12
- 10-Q Quarterly report2026-05-08
- 8-K Earnings results2026-05-07
- 8-K Officer / director change2026-05-04
- DEF 14A Proxy statement2026-04-27
Recent filings
all on EDGAR ↗S-3Filing2026-06-23open ↗4Period ending 2026-06-092026-06-22open ↗8-KPeriod ending 2026-06-102026-06-16open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗S-8Filing2026-06-10open ↗4Period ending 2026-06-042026-06-08open ↗8-KPeriod ending 2026-06-012026-06-02open ↗4Period ending 2026-05-222026-05-27open ↗4Period ending 2026-05-202026-05-22open ↗
Frequently asked
- Is GYRE THERAPEUTICS, INC. (GYRE) a buy?
- GYRE currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Revenue grew 10.2% YoY.
- What is GYRE's fair value?
- A Modified-Graham model based on GYRE's SEC fundamentals estimates a fair value of about $0.17. It is an estimate from reported earnings, not a price target.
- Is GYRE overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, GYRE currently appears overvalued relative to its SEC-grounded earnings power.
- What is GYRE THERAPEUTICS, INC.'s quality score?
- GYRE scores 58.647058823529406/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001124105, latest 10-Q filed 2026-05-08) · EODHD · as of 6/26/2026, 8:15:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.